Canopy Growth Corporation Common Shares
CGCCanopy Growth Corporation is a Canadian-based producer and distributor of cannabis and cannabis-related products. Established in 2013, it is one of the world's leading cannabis companies, focusing on the development and sale of dried flower, oils, capsules, and other cannabis-derived products for both medical and recreational markets. The company operates through various subsidiaries and partnerships, emphasizing research, innovation, and expanding cannabis use across multiple markets globally.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 15, 2007 | $0.24 | 2007-08-01 | 2007-07-31 |
| May 15, 2007 | $0.24 | 2007-04-26 | 2007-04-30 |
| February 15, 2007 | $0.24 | 2007-01-29 | 2007-01-31 |
| November 15, 2006 | $0.24 | 2006-10-27 | 2006-10-31 |
| August 15, 2006 | $0.24 | 2006-07-27 | 2006-07-31 |
Dividends Summary
- Consistent Payer: Canopy Growth Corporation Common Shares has rewarded shareholders with 15 dividend payments over the past 3 years.
- Total Returned Value: Investors who held CGC shares during this period received a total of $3.60 per share in dividend income.
- Latest Payout: The most recent dividend of $0.24/share was paid 6912 days ago, on August 15, 2007.
- Yield & Schedule: CGC currently pays dividends quarterly with an annual yield of 102.14%.
- Dividend Growth: Since 2004, the dividend payout has grown by 0.0%, from $0.24 to $0.24.
- Dividend Reliability: CGC has maintained or increased its dividend for 15 consecutive payments.
Company News
President Trump's executive order to reschedule medical marijuana from Schedule I to Schedule III provides limited benefits to major cannabis companies. While the rescheduling eliminates IRS Section 280E tax restrictions for medical marijuana businesses, it only applies to medical products, not the larger recreational market. Canopy Growth, Tilra...
Canopy Growth reported strong 27% growth in its medical marijuana division in Q4 fiscal 2026, but the rest of the business showed weakness. The recreational marijuana segment grew only 1% in Q4, international cannabis sales fell 7% year-over-year, and the Storz & Bickel vaporizer business declined 14%. The company continues to report negative ear...
Trulieve Cannabis Corp. became the first U.S. cannabis company to list on a major U.S. stock exchange (NYSE: TRLV), enabled by the Trump administration's reclassification of cannabis to Schedule III. The company separated its medical and adult-use operations to meet exchange requirements. Competitors like Curaleaf and Verano are preparing for sim...
The DEA's rescheduling of marijuana from Schedule I to Schedule III in April 2026 was initially seen as historic but has had muted impact. The rescheduling only applies to medical marijuana and provides limited benefits like IRS Section 280E relief. Canopy Growth, a major Canadian cannabis company, cannot fully capitalize on these changes due to ...
Canopy Growth announced it will restate financial results for two years due to a technical accounting error involving share-settled warrants that should have been classified as liabilities rather than equity. The company states the restatement won't impact revenue, operating income, cash flows, or key performance metrics. However, the stock remai...
